Author ORCID Identifier
https://orcid.org/0000-0002-4106-8330
Date of Graduation
12-2020
Document Type
Dissertation (PhD)
Program Affiliation
Immunology
Degree Name
Doctor of Philosophy (PhD)
Advisor/Committee Chair
Jennifer A. Wargo, M.D., M.M.Sci.
Committee Member
Michael A. Davies, M.D., Ph.D.
Committee Member
Richard E. Davis, M.D.
Committee Member
Giulio F. Draetta, M.D., Ph.D.
Committee Member
Padmanee Sharma, M.D., Ph.D.
Abstract
Melanoma is an aggressive malignancy of melanocytes with historically poor outcomes. Melanoma therapy has improved markedly over the past decade with advances in molecularly targeted agents and immunotherapies. Immune checkpoint inhibitors achieve T-cell mediated anti-tumor efficacy by blocking engagement of inhibitory checkpoints on T-cells to overcome immunosuppressive signals from tumor cells and the broader microenvironment. Despite these advances, there are a significant proportion of patients who do not benefit from existing immunotherapy strategies making it a priority to identify and target the mechanisms that confer resistance to therapy. We demonstrate that microRNAs are accurate markers of microenvironment composition with prognostic value for overall survival in melanoma. We also identified networks of microRNA and mRNA expression in melanoma tissue and melanoma cell lines that are associated with previously identified melanoma transcriptomic subsets. These microRNA networks encompass several key oncogenic processes including epithelial to mesenchymal transition and expression of melanoma specific transcription factors including MITF. Furthermore, investigation of these microRNAs in a cohort of PD-1 inhibitor treated melanoma patients identified a survival benefit in patients whose melanomas had high expression of miR-100-5p and miR-125b-5p. These findings indicate that microRNA regulation of gene expression in melanoma is relevant to melanoma biology, composition of the immune microenvironment and outcomes to PD-1 checkpoint blockade.
Keywords
Melanoma, Immunotherapy, MicroRNA
Included in
Cancer Biology Commons, Immunity Commons, Immunotherapy Commons